Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | PGD | P52209 | 3/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannose 6-Phosphate SCHEMBL6245545 | 0.94 | MPI (0.66) | MPIPGDPGK1PGK2LMNA | |
| Mannose 6-Phosphate SCHEMBL6054950 | 0.94 | MPI (0.66) | MPIPGDPGK1PGK2LMNA | |
| Mannose 6-Phosphate SCHEMBL26619699 | 0.94 | MPI (0.66) | MPIPGDPGK1PGK2LMNA | |
| Demannose SCHEMBL18409553 | 0.91 | MPI (0.57) | MPIAKR1B1PGDPGK1PGK2 | |
| Demannose SCHEMBL27876341 | 0.89 | MPI (0.74) | MPIPGDPGK1PGK2LMNA | |
| Xylose SCHEMBL25294613 | 0.89 | MPI (0.68) | MPIPGDPGK1PGK2LMNA | |
| Xylose SCHEMBL1125483 | 0.89 | MPI (0.68) | MPIPGDPGK1PGK2LMNA | |
| Xylose SCHEMBL3257333 | 0.88 | MPI (0.66) | MPIPGDPGK1PGK2LMNA | |
| Adonitol SCHEMBL21407015 | 0.88 | MPI (0.66) | MPIPGDPGK1PGK2LMNA | |
| Ribitol SCHEMBL19329050 | 0.88 | MPI (0.66) | MPIPGDPGK1PGK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380576-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240131166-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230331763-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023167880-A2 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208549-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | Verve Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023015223-A9 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023015223-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4114360-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3152308-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | Solstice Biologics, Ltd. (IE) | 2017-04-12 | — | — | EP | disclosed |
| EP-3066105-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | Solstice Biologics, Ltd. (IE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| EP-2885313-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | The Regents of The University of California (US) | 2015-06-24 | — | — | EP | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2014031575-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | WO | disclosed |
| US-8106022-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | MPI 1441/4885AKR1B1 1898/4885PGD 4334/4885 |
| US-20240131166-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | MPI 1441/4885AKR1B1 1898/4885PGD 4334/4885 |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | MPI 51/4885AKR1B1 2156/4885PGD 1056/4885 |
| US-20230331763-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | RNGTT, NSUN2, RNMT | MPI 1007/4885AKR1B1 4436/4885PGD 4265/4885 |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | RNASE1, NCL, LNPEP | MPI 194/4885AKR1B1 4538/4885PGD 2440/4885 |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | MPI 1441/4885AKR1B1 1898/4885PGD 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.